ProtecT Trial 15-Year Follow-Up May be ‘Very Important’ for Prostate Cancer

Video

Fifteen-year results of the ProtecT prostate cancer trial may support the findings of the study’s 10-year follow-up data, according to an expert from Dana-Farber Cancer Institute.

In an interview with CancerNetwork® during the 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®), Anthony V. D’Amico, MD, PhD, spoke of the anticipated 15-year follow-up data from the ProtecT trial (NCT02044172) evaluating outcomes following active monitoring, radical prostatectomy, and external-beam radiotherapy for patients with prostate cancer.

With a median follow-up of 10 years, investigators of the ProtecT trial concluded that mortality was low regardless of assigned treatment. Additionally, metastases developed in more patients in the active-monitoring group with 6.3 events per 1000 person-years (95% CI, 4.5-8.8) compared with 2.4 events per 1000 person-years (95% CI, 1.4-4.2) for those receiving surgery and 3.0 events per 1000 person-years (95% CI, 1.9-4.9) for those receiving radiotherapy (P = .004).

Disease progression rates in each respective group were 22.9 events per 1000 person-years (95% CI, 19.0-27.5), 8.9 events per 1000 person-years (95% CI, 6.7-11.9), and 9.0 events per 1000 person-years (95% CI, 6.7-12.0; P <.001).

D'Amico, a professor and chair of genitourinary radiation oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, suggested that the 15-year data from the ProtecT study might be consistent with those reported in the 10-year follow-up.

Transcript:

Something that we're all awaiting that will be very important is the 15-year results of the ProtecT trial, which is a study that [randomly assigned] patients between monitoring, radical prostatectomy, radiation, and hormonal therapy. At 10 years, there was a difference in the metastatic rate, doubling the metastatic rate in the active monitoring as opposed to treatment arms, with no difference between the 2 treatments.

The 15-year results will be informative because we know 10-year results are still early. I suspect that the 15-year results might support the 10-year findings. But that's something we're awaiting, and I know that that is supposed to be available in the coming weeks.

Reference

Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415-1424. doi:10.1056/NEJMoa1606220

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content